Adherex has identified a series of small chemical molecules that, in our preliminary studies, have displayed potent N-cadherin antagonist activity. Unlike ADH-1, these molecules are not peptides and are smaller and simpler in structure. Compared to peptides, small chemical molecules are often active after oral administration, more stable and have different potency and toxicity profiles.
Adherex has also identified small peptide molecules that differ in structure from ADH-1 and that have extended stability in plasma. These molecules offer the potential advantages of extended plasma half-life and enhanced potency compared to ADH-1.